Skip to content
OpenCapital
Get started

Utah Medical Products UTMD Effect of dilutive RSUs and PSUs (in shares)

Effect of dilutive RSUs and PSUs (in shares) at other companies

Avanos Medical logo
Avanos MedicalAVNS
1M+42.9%

Other financials

Income statement

See full
Revenue$8.7M-10.2%
Gross profit$5.3M-4.6%
Operating income$2.6M-18.6%
Net income$2.6M-14.4%
EPS (diluted)$0.82-10.9%

Balance sheet

See full
Cash & equivalents$87.4M+4.9%
Total debt$210.0K—
Total equity$120.4M+2.8%
Total assets$124.4M+1.5%

Cash flow

See full
Operating cash flow$3.1M-30.4%
CapEx$130.0K-29.3%
Free cash flow$3.0M-30.4%

Valuation

See full
Market cap$219.63M+26.4%
Enterprise value$132.44M+42.5%
P/E20.3×+6.4×
P/S5.9×+1.4×

Profitability

See full
Gross margin57.9%-0.4pp
Operating margin28.8%-3.9pp
Net margin28.9%-4.1pp
FCF margin34.7%0.0pp

Returns & leverage

See full
Return on equity9.1%-1.4pp
Debt / equity0×—
Current ratio28.6×+6.3×

Where this comes from

Reported directly by Utah Medical Products in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment.

The official record: Utah Medical Products’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's effect of dilutive rsus and psus (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Utah Medical Products's effect of dilutive rsus and psus (in shares)?
Utah Medical Products (UTMD) reported effect of dilutive rsus and psus (in shares) of 0 in Q1 2026.
What is the long-term trend for Utah Medical Products's effect of dilutive rsus and psus (in shares)?
Over 4 years (2021 to 2025), Utah Medical Products's effect of dilutive rsus and psus (in shares) has grown at a -100.0% compound annual growth rate (CAGR), from 44K to 0.
What does effect of dilutive rsus and psus (in shares) mean?
This represents the incremental number of shares that would be issued if all outstanding dilutive instruments, such as restricted stock units (RSUs) and performance stock units (PSUs), were vested or exercised. It quantifies the potential dilution to existing shareholders from equity-based incentive plans. Investors use this to gauge the potential impact of future share issuance on ownership stakes.